Cells diversify transmembrane signaling through the controlled chaos of protein disorder

Self/Nonself - Immune Recognition and Signaling

Volumn 2, Issue 2, 2011, Pages 75-79

  Sigalov, Alexander B ^a  

^a SignaBlok Inc   (United States)

Author keywords

Cell receptors; Immune signaling; Intrinsically disordered proteins; MIRR; Mul tichain receptors; Multichain immune recognition receptors; Protein disorder; Protein order; Receptor signaling; SCHOOL concept; Single chain receptors

Indexed keywords

B LYMPHOCYTE RECEPTOR; CELL SURFACE RECEPTOR; GLYCOPROTEIN VI; IMMUNOGLOBULIN A FC RECEPTOR TYPE I; IMMUNOGLOBULIN E FC RECEPTOR TYPE I; IMMUNOGLOBULIN G FC RECEPTOR TYPE I; IMMUNOGLOBULIN G FC RECEPTOR TYPE IIIA; IMMUNOGLOBULIN RECEPTOR; LECTIN RECEPTOR; LYMPHOTOXIN; MEMBRANE PROTEIN; MYELOID ASSOCIATED IG LIKE RECEPTOR; MYELOID DAP12 ASSOCIATING LECTIN 1; NATURAL KILLER CELL RECEPTOR; PROTEIN TYROSINE KINASE; T LYMPHOCYTE RECEPTOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL ACTIVATION; CYTOPLASM; HETERONUCLEAR SINGLE QUANTUM COHERENCE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; NUCLEAR MAGNETIC RESONANCE; PROTEIN AGGREGATION; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 80053110777     PISSN: 19382030     EISSN: 19382049     Source Type: Journal    
DOI: 10.4161/self.2.2.15756     Document Type: Article

References (56)

1. Sigalov A, Aivazian D, Stern L. Homooligomerization of the cytoplasmic domain of the T cell receptor zeta chain and of other proteins containing the immunoreceptor tyrosine-based activation motif. Biochemistry 2004; 43:2049-61.
2. Sigalov AB. Protein intrinsic disorder and oligomeric-ity in cell signaling. Mol Biosyst 2010; 6:451-61.
3. Sigalov AB. The SCHOOL of nature. II. Protein order, disorder and oligomericity in transmembrane signaling. Self/Nonself 2010; 1:89-102.
4. Sigalov AB, Aivazian DA, Uversky VN, Stern LJ. Lipid-Binding activity of intrinsically unstructured cytoplasmic domains of multi chain immune recognition receptor signaling subunits. Biochemistry 2006; 45:15731-9.
5. Sigalov AB, Uversky VN. Differential occurrence of protein intrinsic disorder in the cytoplasmic signaling domains of cell receptors. Self/Nonself 2011; 2:55-72.
6. Sigalov AB. Unusual biophysics of immune signaling-related intrinsically disordered proteins. Self/Nonself 2010; 1:271-81.
7. Sigalov AB, Hendricks GM. Membrane binding mode of intrinsically disordered cytoplasmic domains of T cell receptor signaling subunits depends on lipid composition. Biochem Biophys Res Commun 2009; 389:388-93.
8. Sigalov AB, Kim WM, Saline M, Stern LJ. The intrinsically disordered cytoplasmic domain of the T-cell receptor zeta chain binds to the nef protein of simian immunodeficiency virus without a disorder-to-order transition. Biochemistry 2008; 47:12942-4.
9. Sigalov AB, Zhuravleva AV, Orekhov VY. Binding of intrinsically disordered proteins is not necessarily accompanied by a structural transition to a folded form. Biochimie 2007; 89:419-21.
10. Sigalov AB. Multichain immune recognition receptor signaling: Different players, same game? Trends Immunol 2004; 25:583-9.
11. Sigalov AB. The SCHOOL of nature. I. Transmembrane signaling. Self/Nonself 2010; 1:4-39.
12. Keegan AD, Paul WE. Multichain immune recognition receptors: Similarities in structure and signaling pathways. Immunol Today 1992; 13:63-8.
13. Reth M. Antigen receptor tail clue. Nature 1989; 338:383-4.
14. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL. DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med 2000; 192:1059-68.
15. Kishimoto H, Kubo RT, Yorifuji H, Nakayama T, Asano Y, Tada T. Physical dissociation of the TCR-CD3 complex accompanies receptor ligation. J Exp Med 1995; 182:1997-2006.
16. Kosugi A, Saitoh S, Noda S, Yasuda K, Hayashi F, Ogata M et al. Translocation of tyrosine-phosphor-ylated TCRzeta chain to glycolipid-enriched membrane domains upon T cell activation. Int Immunol 1999; 11:1395-401.
17. La Gruta NL, Liu H, Dilioglou S, Rhodes M, Wiest DL, Vignali DA. Architectural changes in the TCR:CD3 complex induced by MHC:Peptide liga-tion. J Immunol 2004; 172:3662-9.
18. Liu H, Rhodes M, Wiest DL, Vignali DA. On the dynamics of TCR:CD3 complex cell surface expression and down modulation. Immunity 2000; 13:665-75.
19. Kim JH, Cramer L, Mueller H, Wilson B, Vilen BJ. Independent trafficking of Ig-alpha/Ig-beta and mu-heavy chain is facilitated by dissociation of the B cell antigen receptor complex. J Immunol 2005; 175:147-54.
20. Kremyanskaya M, Monroe JG. Ig-independent Ig beta expression on the surface of B lymphocytes after B cell receptor aggregation. J Immunol 2005; 174:1501-6.
21. Vilen BJ, Nakamura T, Cambier JC. Antigen-stimulated dissociation of BCR mIg from Ig-alpha/ Ig-beta: implications for receptor desensitization. Immunity 1999; 10:239-48.
22. Asai K, Fujimoto K, Harazaki M, Kusunoki T, Korematsu S, Ide C, et al. Distinct aggregation of beta- and gamma-chains of the high-affinity IgE receptor on cross-linking. J Histochem Cytochem 2000; 48:1705-16.
23. Archakov AI, Govorun VM, Dubanov AV, Ivanov YD, Veselovsky AV, Lewi P, et al. Protein-protein interactions as a target for drugs in proteomics. Proteomics 2003; 3:380-91.
24. Pagliaro L, Felding J, Audouze K, Nielsen SJ, Terry RB, Krog-Jensen C, et al. Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol 2004; 8:442-9.
25. Veselovsky AV, Archakov AI. Inhibitors of protein-protein interactions as potential drugs. Current Computer-Aided Drug Design 2007; 3:51-8.
26. Sigalov AB. Immune cell signaling: A novel mechanistic model reveals new therapeutic targets. Trends Pharmacol Sci 2006; 27:518-24.
27. Sigalov AB. Interaction between HIV gp41 fusion peptide and T cell receptor: Putting the puzzle pieces back together. Faseb J 2007; 21:1633-4.
28. Sigalov AB. Novel mechanistic insights into viral modulation of immune receptor signaling. PLoS Pathog 2009; 5:1000404.
29. Sigalov AB. The SCHOOL of nature. IV. Learning from viruses. Self/Nonself 2010; 1:282-98.
30. Quintana FJ, Gerber D, Kent SC, Cohen IR, Shai Y. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest 2005; 115: 2149-58.
31. Sigalov AB. Novel mechanistic concept of platelet inhibition. Expert Opin Ther Targets 2008; 12:677-92.
32. Sigalov AB. New therapeutic strategies targeting transmembrane signal transduction in the immune system. Cell Adh Migr 2010; 4:255-67.
33. Sigalov AB. The SCHOOL of nature. III. From mechanistic understanding to novel therapies. Self/ Nonself 2010; 1:192-224.
34. Quintana FJ, Gerber D, Bloch I, Cohen IR, Shai Y. A structurally altered D, L-amino acid TCRalpha transmembrane peptide interacts with the TCRalpha and inhibits T-cell activation in vitro and in an animal model. Biochemistry 2007; 46:2317-25.
35. Kurosaka N, Ali M, Byth K, Manolios N. The mode of anti-arthritic peptide delivery impacts on the severity and outcome of adjuvant induced arthritis. APLAR J Rheumatol 2007; 10:198-203.
36. Manolios N, Ali M, Amon M, Bender V. Therapeutic application of transmembrane T and natural killer cell receptor peptides. Adv Exp Med Biol 2008; 640:208-19.
37. Manolios N, Ali M, Bender V. T-cell antigen receptor (TCR) transmembrane peptides: A new paradigm for the treatment of autoimmune diseases. Cell Adh Migr 2010; 4:273-83.
38. Manolios N, Huynh NT, Collier S. Peptides in the treatment of inflammatory skin disease. Australas J Dermatol 2002; 43:226-7.
39. Pitcher LA, van Oers NS. T-cell receptor signal transmission: Who gives an ITAM? Trends Immunol 2003; 24:554-60.
40. Sickmeier M, Hamilton JA, LeGall T, Vacic V, Cortese MS, Tantos A, et al. DisProt: The database of disordered proteins. Nucleic Acids Res 2007; 35:786-93.
41. Patil A, Nakamura H. Disordered domains and high surface charge confer hubs with the ability to interact with multiple proteins in interaction networks. FEBS Lett 2006; 580:2041-5.
42. Sigalov AB. Signaling chain homooligomeriza-tion (SCHOOL) model. Adv Exp Med Biol 2008; 640:121-63.
43. Sigalov A. Multi-chain immune recognition receptors: spatial organization and signal transduction. Semin. Immunol 2005; 17:51-64.
44. Pike KA, Baig E, Ratcliffe MJ. The avian B-cell receptor complex: Distinct roles of Igalpha and Igbeta in B-cell development. Immunol Rev 2004; 197:10-25.
45. Storch B, Meixlsperger S, Jumaa H. The Ig-alpha ITAM is required for efficient differentiation but not proliferation of pre-B cells. Eur J Immunol 2007; 37:252-60.
46. Gazumyan A, Reichlin A, Nussenzweig MC. Ig beta tyrosine residues contribute to the control of B cell receptor signaling by regulating receptor internaliza-tion. J Exp Med 2006; 203:1785-94.
47. Lin S, Cicala C, Scharenberg AM, Kinet JP. The Fc(epsilon)RIbeta subunit functions as an amplifier of Fc(epsilon)RIgamma-mediated cell activation signals. Cell 1996; 85:985-95.
48. Sanchez-Mejorada G, Rosales C. Signal transduction by immunoglobulin Fc receptors. J Leukoc Biol 1998; 63:521-33.
49. Lysechko TL, Ostergaard HL. Differential Src family kinase activity requirements for CD3 zeta phos-phorylation/ZAP70 recruitment and CD3 epsilon phosphorylation. J Immunol 2005; 174:7807-14.
50. Kuhns MS, Davis MM. Disruption of extracellular interactions impairs T cell receptor-CD3 complex stability and signaling. Immunity 2007; 26:357-69.
51. Chau LA, Bluestone JA, Madrenas J. Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor. J Exp Med 1998; 187:1699-709.
52. Jensen WA, Pleiman CM, Beaufils P, Wegener AM, Malissen B, Cambier JC. Qualitatively distinct signaling through T cell antigen receptor subunits. Eur J Immunol 1997; 27:707-16.
53. Pitcher LA, Mathis MA, Young JA, Deford LM, Purtic B, Wulfing C, et al. The CD3 gammaepsilon/ deltaepsilon signaling module provides normal T cell functions in the absence of the TCR zeta immu-noreceptor tyrosine-based activation motifs. Eur J Immunol 2005; 35:3643-54.
54. Kesti T, Ruppelt A, Wang JH, Liss M, Wagner R, Tasken K, et al. Reciprocal regulation of SH3 and SH2 domain binding via tyrosine phosphorylation of a common site in CD3{epsilon}. J Immunol 2007; 179:878-85.
55. Roifman CM. CD3 delta immunodeficiency. Curr Opin Allergy Clin Immunol 2004; 4:479-84.
56. Chae WJ, Lee HK, Han JH, Kim SW, Bothwell AL, Morio T, et al. Qualitatively differential regulation of T cell activation and apoptosis by T cell receptor zeta chain ITAMs and their tyrosine residues. Int Immunol 2004; 16:1225-36.